ImmuCell (ICCC) vs Lantheus (LNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed ImmuCell (ICCC) over the past year, gaining 93.2% versus a gain of 50.2%. Over five years, LNTH leads with a +330.7% price change compared with +4.4% for ICCC. Lantheus is the larger company by market cap ($6.55 billion vs $88.5 million), about 74.0 times the size.
On valuation, Lantheus trades at a lower trailing P/E (24.3x vs 139.1x for ImmuCell).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | LNTH |
|---|---|---|
| Share price | $9.74 | $100.24 |
| Market cap | $88.46M | $6.55B |
| 1-day change | +0.52% | +0.06% |
| YTD return | +57.56% | +50.53% |
| 1-year return | +50.23% | +93.25% |
| 5-year return | +4.42% | +330.70% |
| P/E ratio (TTM) | 139.14 | 24.27 |
| Forward P/E | — | 15.72 |
| EPS (TTM) | $0.07 | $4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.54B |
| Revenue growth (YoY) | — | +0.50% |
| Net income (latest FY) | — | $233.56M |
| Gross margin | — | 61.10% |
| Operating margin | — | 20.16% |
| Net margin | — | 15.15% |
| 52-week high | $12.10 | $111.86 |
| 52-week low | $4.52 | $50.16 |
| Distance from 52-week high | -19.50% | -10.39% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +7.48% |
| Average volume | 22.88K | 1.32M |
| Shares outstanding | 9.08M | 65.30M |
| Employees | — | 1,193 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 74.0 times larger than ImmuCell by market value ($6.55B vs $88.46M).
- LNTH has outperformed ICCC by 43.0 percentage points over the past year.
- ImmuCell trades at a higher earnings multiple (139.1x vs 24.3x trailing P/E).
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
ICCC vs LNTH FAQ
Which is bigger, ImmuCell or Lantheus?
Lantheus (LNTH) is larger, with a market capitalization of $6.55B compared with $88.46M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or LNTH?
LNTH returned +93.25% over the past 12 months, compared with +50.23% for ICCC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ICCC or LNTH?
LNTH has the lower trailing P/E at 24.3, versus 139.1 for ICCC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ImmuCell and Lantheus in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.